Longer-term treatment of patients with bipolar disorder: A 9-month observational study in Central and Eastern Europe, the Middle East and Africa

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 1889-1900

  Okasha, Tarek A ^a   Kučukali, Abdulah ^b   Nasr, Aly Akram A ^c   Zelman, Marek ^d   Karamustafalioǧlu, Oguz ^e   Sir, Aytekin ^f   Harrison, Gavan ^g   Treuer, Tamás ^h  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b Klinicki Centar Univerziteta Sarajevo   (Bosnia and Herzegovina)

^c Suliman Fakeeh Hospital   (Saudi Arabia)

^d NsP Brezno   (Slovakia)

^e Norosirurji Klinigi Sisli   (Turkey)

^f DICLE UNIVERSITY   (Turkey)

^g Intercontinental Information Sciences   (Australia)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic agents; Bipolar disorder; Olanzapine; Treatment outcomes

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; AFRICA; AKATHISIA; AMNESIA; ARTICLE; BIPOLAR MANIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG SAFETY; DYSTONIA; EUROPE; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITAL PATIENT; HUMAN; HYPOMANIA; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MIDDLE EAST; NOCTURIA; OUTPATIENT; PARKINSONISM; POLYURIA; REMISSION; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR;

ADULT; AFRICA; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; EUROPE; EUROPE, EASTERN; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; MIDDLE EAST; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67650831186     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903070270     Document Type: Article

References (29)

1. Salvatore P, Tohen M, Khalsa HM, et al. Longitudinal research on bipolar disorders. Epidemiol Psichiatr Soc 2007;16:109-17
2. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR). 4th edn. Arlington VA: American Psychiatric Association, 2000
3. Gajwani P, Kemp DE, Muzina DJ, et al. Acute treatment of mania: an update on new medications. Curr Psychiatry Rep 2006;8:504-9
4. Mitchell PB, Malhi GS. The expanding pharmacopoeia for bipolar disorder. Annu Rev Med 2002;53:173-88
5. Zhu B, Kulkarni PM, Stensland MD, et al. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. Curr Med Res Opin 2007;23:2805-14
6. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003;73:123-31
7. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEPBD). Am J Psychiatry 2006;163:217-24
8. Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007;7:40
9. Jones RM, Thompson C, Bitter I . A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. Eur Psychiatry 2006;21:1-9
10. Treuer T, Oruc L, Loza N, et al. Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes. Psychiatr Danub 2007;19:282-95
11. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159-71
12. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35
13. Gonzalez-Pinto A, Ballesteros J, Aldama A, et al. Principal components of mania. J Affect Disord 2003;76:95-102
14. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
15. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
16. Faries D, Ascher-Svanum H, Belger M. Analysis of treatment effectiveness in longitudinal observational data. J Biopharm Stat 2007;17:809-26
17. Joffe MM, Ten Have TR, Feldman HI, et al. Model selection, confounder control, and marginal structural models: review and new applications. Am Stat 2004;58:272-9
18. Vieta E, Panicali F, Goetz I , et al. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord 2008;106:63-72
19. Hirschfeld RA, Bowden CL, Gitlin MJ, et al. Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd edn. American Psychiatric Association, 2002. Available at: http://www.psychiatryonline.com/pracGuide/ pracGuideTopic-8.aspx [Last accessed 4 April 2008]
20. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263-71
21. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45
22. Fagiolini A, Kupfer DJ, Masalehdan A, et al. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord 2005;7:281-5
23. Shi L, Juarez R, Hackworth J, et al. Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes. Curr Med Res Opin 2006;22:961-6
24. Henderson DC. Weight gain with atypical antipsychotics: evidence and insights. J Clin Psychiatry 2007;68(Suppl 12):18-26
25. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003;64:1426-35
26. Hennen J, Perlis RH, Sachs G, et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry 2004;65:1679-87
27. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247-56
28. National Heart Lung and Blood Institute & National Institute of Diabetes and Digestive and Kidney Diseases. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Publication 98-4083. 1998. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.html [Last accessed 4 April 2008]
29. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008;7:93-106